Search research articles
Contact Us
Filters
Showing results (31-40 of 372) with videos related to
Page
of 38
Sort By:
JAMA Oncology
|
November 3, 2022
Association of Hormone Receptors With Clinical Outcomes in Patients With ERBB2-Low Breast Cancer-Reply
Paolo Tarantino, Nabihah Tayob, Sara M Tolaney
Clinical Advances in Hematology & Oncology : H&O
|
June 13, 2019
How we treat locally advanced HER2-positive breast cancer
Pedro Exman, Sonia Pernas, Sara M Tolaney
Cancers
|
August 26, 2022
Overcoming Resistance to HER2-Directed Therapies in Breast Cancer
Ilana Schlam, Paolo Tarantino, Sara M Tolaney
Endocrine-Related Cancer
|
September 5, 2024
Association between pembrolizumab-related thyroid adverse events and outcomes in early-stage triple-negative breast cancer patients
Marta Villanova, Sara M Tolaney, Le Min
Breast (Edinburgh, Scotland)
|
January 20, 2023
How I treat HER2-low advanced breast cancer
Ilana Schlam, Sara M Tolaney, Paolo Tarantino
Expert Opinion on Drug Safety
|
November 23, 2023
Interstitial lung disease and CDK4/6 inhibitors in the treatment of breast cancer
Ilana Schlam, Antonio Giordano, Sara M Tolaney
Expert Opinion on Biological Therapy
|
October 6, 2023
Managing adverse events of sacituzumab govitecan
Ilana Schlam, Paolo Tarantino, Sara M Tolaney
Cancer Discovery
|
July 20, 2022
Navigating the HER2-Low Paradigm in Breast Oncology: New Standards, Future Horizons
Paolo Tarantino, Giuseppe Curigliano, Sara M Tolaney
JAMA Oncology
|
September 22, 2022
Etirinotecan Pegol Treatment for Patients With Metastatic Breast Cancer and Brain Metastases-Reply
Debu Tripathy, Sara M Tolaney, Mary Tagliaferri
Expert Review of Anticancer Therapy
|
January 24, 2023
The efficacy of trastuzumab-deruxtecan for the treatment of patients with advanced HER2-low breast cancer
Ilana Schlam, Sara M Tolaney, Paolo Tarantino
Page
of 38
Search research articles
Search
Showing results (31-40 of 372) with videos related to
Sort By:
Page
of 38
JAMA Oncology
|
November 3, 2022
Association of Hormone Receptors With Clinical Outcomes in Patients With ERBB2-Low Breast Cancer-Reply
Paolo Tarantino, Nabihah Tayob, Sara M Tolaney
Clinical Advances in Hematology & Oncology : H&O
|
June 13, 2019
How we treat locally advanced HER2-positive breast cancer
Pedro Exman, Sonia Pernas, Sara M Tolaney
Cancers
|
August 26, 2022
Overcoming Resistance to HER2-Directed Therapies in Breast Cancer
Ilana Schlam, Paolo Tarantino, Sara M Tolaney
Endocrine-Related Cancer
|
September 5, 2024
Association between pembrolizumab-related thyroid adverse events and outcomes in early-stage triple-negative breast cancer patients
Marta Villanova, Sara M Tolaney, Le Min
Breast (Edinburgh, Scotland)
|
January 20, 2023
How I treat HER2-low advanced breast cancer
Ilana Schlam, Sara M Tolaney, Paolo Tarantino
Expert Opinion on Drug Safety
|
November 23, 2023
Interstitial lung disease and CDK4/6 inhibitors in the treatment of breast cancer
Ilana Schlam, Antonio Giordano, Sara M Tolaney
Expert Opinion on Biological Therapy
|
October 6, 2023
Managing adverse events of sacituzumab govitecan
Ilana Schlam, Paolo Tarantino, Sara M Tolaney
Cancer Discovery
|
July 20, 2022
Navigating the HER2-Low Paradigm in Breast Oncology: New Standards, Future Horizons
Paolo Tarantino, Giuseppe Curigliano, Sara M Tolaney
JAMA Oncology
|
September 22, 2022
Etirinotecan Pegol Treatment for Patients With Metastatic Breast Cancer and Brain Metastases-Reply
Debu Tripathy, Sara M Tolaney, Mary Tagliaferri
Expert Review of Anticancer Therapy
|
January 24, 2023
The efficacy of trastuzumab-deruxtecan for the treatment of patients with advanced HER2-low breast cancer
Ilana Schlam, Sara M Tolaney, Paolo Tarantino
Page
of 38